Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Theoretical concerns exist that oculotoxic effects of risdiplam, observed in monkeys, may be additive with those of other drugs that are associated with retinotoxicity. Chronic treatment of monkeys with risdiplam showed photoreceptor degeneration starting in the periphery of the retina. Upon cessation of treatment, the effects on the retinogram were partially reversible but the retinal degeneration, with peripheral photoreceptor loss, was irreversible. A no-effect dose for the retinal findings (1.5 mg/kg/day) in monkeys was associated with plasma exposures (AUC) like that in humans at the maximum recommended human dose (MRHD) of 5 mg. However, the potential for synergistic effects of concomitant administration of risdiplam with retinotoxic drugs has not been studied.

MANAGEMENT: Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs. These drugs may include infigratinib, selumetinib, cobimetinib, vigabatrin, chloroquine, hydroxychloroquine, thioridazine and deferoxamine.

Food may delay and reduce the absorption of trametinib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take trametinib at least 1 hour before or 2 hours after a meal.